Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gigacloud Technology Inc (GCT) vs Eli Lilly And Co (LLY) Price & Performance

Gigacloud Technology IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Gigacloud Technology Inc vs Eli Lilly And Co — how do they compare? Gigacloud Technology Inc trades at $38.02 (market cap $1.40B), while Eli Lilly And Co trades at $1,176.5 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 735.7× Gigacloud Technology Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.

GCTLLY
Market Cap
$1.40B$1.03T
Sector
TechnologyHealth
52-Week High
$51.80$1.24K
52-Week Low
$20.97$625.65
Enterprise Value
$1.51B$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gigacloud Technology Inc

GigaCloud Technology (GCT) trades at $37.85, up 6.91% with strong earnings momentum after beating Q1 2026 EPS estimates. The stock shows bullish technical signals despite mixed indicators, with valuation ratios appearing attractive (P/E 9.49, P/S 1.02). Recent recognition as TIME's World Growth Leader and expanding international presence highlight operational strength.

GCT presents compelling value with robust profitability (32.14% ROE) and consistent earnings beats, though technical overbought conditions and competitive pressures warrant caution. The 66.7% analyst buy rating supports upside potential, but investors should monitor execution risks in international expansion.

Eli Lilly And Co

LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.

Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gigacloud Technology Inc

Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.

Read more on GCT

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY